Mazama Energy raised $135 million, led by Centaurus Capital and Doerr Capital, to fund Project Ceres at Newberry. The round follows a drilling milestone: the Athena well reached 10,350 feet in 15 days, 80% faster than the company's 2025 record well.
Ultragenyx won the first-ever FDA approval for a Sanfilippo syndrome type A therapy, priced at $3.95 million per patient. The win lands eight days after an Angelman Phase 3 failure cut about 44% of its market value, leaving investors to weigh a first-in-disease asset against a tiny patient pool.
Delos Data raised more than $100 million on September 15 to build the interconnect layer for AI data centers. Its thesis: the network, not compute, is the next bottleneck for inference — and capital is rotating toward whoever keeps heterogeneous chips talking.
Europe's newest space unicorn closed a €300M Series C on the strength of four European plants, a one-satellite-a-day production line, and five straight years of profit.
Ursa Major Technologies is going public through a $2.3 billion SPAC to fund solid rocket motor and hypersonics production. The bull case is a third supplier breaking a two-company duopoly; the bear case is redemption risk and quarterly reporting colliding with multi-year qualification cycles.
Thea Energy's Helios design targets roughly 400 MW of grid power with software-controlled flat magnets instead of complex 3D coils. Sixteen peer-reviewed papers back the engineering. The remaining questions are cost, construction and a 2030s deadline.
Sling Therapeutics closed a $123M Series C and dosed the first patients in a Phase 3 trial of linsitinib, an oral IGF-1R inhibitor for thyroid eye disease. The bet is convenience against the infused antibody class — and the readout is not due before 2028.
Runware's Sonic Inference Pod puts 1 MW and about 1,200 GPUs into a 20-foot container with water-free cooling. Facilities cost runs up to 100x below a gigawatt-scale build, and the company targets 160 sites and more than 1 GW by 2027.